| Literature DB >> 24422745 |
Saiful Anuar Karsani1, Nor Afiza Saihen, Rosnah Binti Zain, Sok-Ching Cheong, Mariati Abdul Rahman.
Abstract
BACKGROUND: A limiting factor in performing proteomics analysis on cancerous cells is the difficulty in obtaining sufficient amounts of starting material. Cell lines can be used as a simplified model system for studying changes that accompany tumorigenesis. This study used two-dimensional gel electrophoresis (2DE) to compare the whole cell proteome of oral cancer cell lines vs normal cells in an attempt to identify cancer associated proteins.Entities:
Year: 2014 PMID: 24422745 PMCID: PMC3974152 DOI: 10.1186/1477-5956-12-3
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Figure 1Representative 2DE gel of whole cell proteome of cell lines. The whole cell protein of normal primary cultures and cancer cell lines were resolved by 2DE pI 4–7, 11% second dimension polyacrylamide gel. Proteins with different abundance are shown as numbered spots. The numbers correspond to Spot Number in Table 1.
List of proteins with different abundance in cancer cell lines
| Structural | ||||||||
| 20 | Stathmin (Phosphoprotein p19) | P16949 /SPOT 2D-001YH8 | 17.3/5.76 | >15.0/5.7 | 4 (18%) | +1.6 | ||
| STMN1 | ||||||||
| 1 | Tropomyosin alpha-3 chain (Tropomyosin-3) | P06753 / | 32.8/4.68 | >30.0/4.6 | 6 (13%) | -1.5 | ||
| SPOT 2D-001EM1 | ||||||||
| SPOT 2D-001YBH | ||||||||
| TPM3 | SPOT 2D-001JNO | |||||||
| 4 | Myosin regulatory light chain-2 | P19105 / | 19.8/4.67 | >15.0/4.60 | 5 (17%) | -1.9 | ||
| SPOT 2D-001JUH | ||||||||
| ML12A | SPOT 2D-001JUS | |||||||
| Enzymes | ||||||||
| 6 | Lactoylglutathione lyase (Glyoxalase I). (EC 4.4.1.5) | Q04760 / | 20.8/5.12 | >20.0/5.00 | 10 (22%) | +7.7 | ||
| LGUL | n/a | |||||||
| 24 | Triosephosphate isomerase (EC 5.3.1.1) | P60174 / | 26.7/6.45 | >25.0/6.5 | 5 (28%) | +2.5 | ||
| TPIS | SPOT 2D-0003MP | |||||||
| 18 | Nucleoside diphosphate kinase A (EC 2.7.4.6) | P15531 / | 17.1/5.83 | >15.0/5.8 | 8 (31%) | +1.5 | ||
| NDKA | n/a | |||||||
| 21 | Ubiquitin-conjugating enzyme E2 N (EC 6.3.2.19) | P61088 / | 17.1/6.13 | >15.0/5.9 | 6 (23%) | +2.6 | ||
| UBE2N | n/a | |||||||
| 16 | Gamma-glutamylcyclotransferase (EC 2.3.2.4) | O75223 / | 21.0/5.07 | >20.0/5.0 | 3 (27%) | +2.5 | ||
| GGCT | n/a | |||||||
| 14 | Peroxiredoxin-4 (EC 1.11.1.15) | Q13162 / | 30.5/5.86 | >30.0/5.8 | 6 (16%) | +2.2 | ||
| PRDX4 | n/a | |||||||
| 19 | Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) | P00441 / | 15.9/5.70 | >15.0/5.70 | 5 (24%) | +1.4 | ||
| SPOT 2D-001F1V | ||||||||
| SODC | SPOT 2D-000ZXR | |||||||
| 17 | Glutathione S-transferase P (GST class-pi). (EC 2.5.1.18) | P09211 / | 23.3/5.43 | >25/5.6 | 8 (22%) | +1.4 | ||
| SPOT 2D-001EUM | ||||||||
| SPOT 2D-0003Q9 | ||||||||
| GSTP1 | SPOT 2D-00085X | |||||||
| 11 | Proteasome subunit beta type 4 precursor. (EC 3.4.25.1) | P28070 / | 29.2/5.72 | 29.0/5.7 | 6 (15%) | +1.6 | ||
| SPOT 2D-000851 | ||||||||
| PSB4 | SPOT 2D-000D4M | |||||||
| Regulatory proteins | ||||||||
| 3 | 14-3-3 protein beta/alpha | P31946 / | 28.0/4.70 | >25.0/4.50 | 6 (4%) | +1.8 | ||
| 1433B | n/a | |||||||
| 12 | Prohibitin | P35232 / | 29.8/5.57 | >25.0/5.60 | 5 (12%) | +1.6 | ||
| PHB | SPOT 2D-001EOL | |||||||
| 13 | Proteasome activator complex subunit 1 | Q06323 / | 28.7/5.78 | >25.0/5.70 | 2 (4%) | -1.7 | ||
| PSME1 | SPOT 2D-001YC7 | |||||||
| 16 | Proteasome activator complex subunit 2 | Q9UL46 / | 27.3/5.44 | >30.0/5.4 | 4 (11%) | -2.3 | ||
| PSME2 | n/a | |||||||
| 2 | 14-3-3 protein sigma (Stratifin) | P31947 / | 27.8/4.68 | >25.0/4.50 | 9 (24%) | -2.0 | ||
| 1433S | SPOT 2D-001EP6 | |||||||
| 22 | Stress-induced-phosphoprotein 1 | P31948 / | 62.6/6.4 | >55.0/6.50 | 11 (12%) | +2.1 | ||
| STIP1 | n/a | |||||||
| 10 | Interleukin-1 receptor antagonist protein precursor | P18510 / | 20.0/5.83 | >20.0/5.3 | 2 (8%) | +1.3 | ||
| IL1RA | n/a | |||||||
| 5 | Rho GDP-dissociation inhibitor 1 | P52565 / | 23.2/5.02 | 30.0/5.0 | 4 (14%) | +2.6 | ||
| GDIR | n/a | |||||||
| 9 | Ran-specific GTPase-activating protein | P43487 / | 23.3/5.19 | 30/5.2 | 5 (18%) | +1.8 | ||
| RANG | n/a | |||||||
| Chaperones | ||||||||
| 15 | Heat-shock protein beta-1 | P04792 / | 22.8/6.00 | >20.0/5.8 | 11 (32%) | +3.1 | ||
| SPOT 2D-001JQI | ||||||||
| HSPB1 | SPOT 2D-001JQP | |||||||
| 23 | T-complex protein 1 subunit zeta-2 | Q92526 / | 57.7/6.63 | >55.0/6.8 | 2 (2%) | -1.6 | ||
| TCPW | n/a | |||||||
| Others | ||||||||
| 8 | Chloride intracellular channel protein 1 (membrane associated) | O00299 / | 26.9/5.09 | >30.0/5.1 | 14 (46%) | -1.7 | ||
| CLIC1 | SPOT 2D-001YBL | |||||||
The proteins were grouped into five functional categories – structural proteins, enzymes, regulatory proteins, chaperones and others. The accession number (swiss-prot) and matched 2D coordinates, molecular weight and pI (theoretical and experimental), number of matched peptides, percentage coverage, relative change vs normal and zoomed in gel image showing representative spots are shown.
Proteins that are known to be cancer associated based on IPA
| Cancer | Cervical tumor | 1.55E-04 | GSTP1, HSPB1, PHB, TPM3 | 4 |
| Cancer | Breast cancer | 1.82E-04 | GGCT, GLO1, GSTP1, NME1, PHB, RANBP1, SOD1, TPI1 | 8 |
| Cancer | Nodular hyperplasia of liver | 1.25E-03 | SOD1 | 1 |
| Cancer | Hematological neoplasia | 1.89E-03 | CCT6B, GSTP1, NME1, PSME1, STIP1, STMN1 | 6 |
| Cancer | Lymphohematopoietic cancer | 2.21E-03 | CCT6B, GSTP1, NME1, PSME1, STIP1, STMN1 | 6 |
| Cancer | Cervical cancer | 2.44E-03 | GSTP1, HSPB1, TPM3 | 3 |
| Cancer | Multiplicity of benign tumor | 2.50E-03 | GSTP1 | 1 |
| Cancer | Neuroblastoma | 3.33E-03 | GSTP1, NME1 | 2 |
| Cancer | Epidermal hyperplasia | 4.24E-03 | PHB, RANBP1 | 2 |
| Cancer | Metastasis of melanoma | 4.99E-03 | IL1RN | 1 |
| Cancer | Gastric cancer | 5.75E-03 | GSTP1, IL1RN, PHB | 3 |
| Cancer | Digestive organ tumor | 6.00E-03 | GSTP1, IL1RN, NME1, PHB, SFN, SOD1, STIP1, TPI1 | 8 |
| Cancer | Invasion of trophoblast | 7.48E-03 | NME1 | 1 |
| Cancer | Urothelial bladder carcinoma | 7.48E-03 | GSTP1 | 1 |
| Cancer | Non-small cell lung cancer | 7.89E-03 | GSTP1, MYL12A, STMN1 | 3 |
| Cancer | Cancer | 8.08E-03 | CCT6B, GGCT, GLO1, GSTP1, HSPB1, IL1RN, MYL12A, NME1, PHB, PSME1, RANBP1, SFN, SOD1, STIP1, STMN1, TPI1, TPM3 | 17 |
| Cancer | Liver cancer | 9.35E-03 | GSTP1, NME1, SOD1, TPI1 | 4 |
| Cancer | Immortalization of keratinocytes | 9.96E-03 | SFN | 1 |
| Cancer | Invasion of extracellular matrix | 1.12E-02 | NME1 | 1 |
| Cancer | Neoplasia of cells | 1.21E-02 | NME1, PHB, SFN | 3 |
| Cancer | Hematologic cancer | 1.27E-02 | GSTP1, NME1, PSME1, STIP1 | 4 |
| Cancer | Hereditary diffuse gastric cancer | 1.37E-02 | IL1RN | 1 |
| Cancer | Growth of secondary tumor | 1.49E-02 | IL1RN | 1 |
| Cancer | Incidence of hepatocellular carcinoma | 1.49E-02 | SOD1 | 1 |
| Cancer | Quantity of papilloma | 1.61E-02 | GSTP1 | 1 |
| Cancer | Metastasis of cells | 1.71E-02 | NME1, PHB | 2 |
| Cancer | Hepatocellular carcinoma | 2.21E-02 | NME1, SOD1, TPI1 | 3 |
| Cancer | Follicular adenoma | 2.23E-02 | GSTP1 | 1 |
| Cancer | Waldenstrom’s macroglobulinemia | 2.26E-02 | NME1,STIP1 | 2 |
| Cancer | Acute myeloid leukemia | 2.31E-02 | GSTP1, PSME1 | 2 |
| Cancer | Tumorigenesis of colon cancer cell lines | 2.35E-02 | SFN | 1 |
| Cancer | Metastasis of cancer cells | 2.96E-02 | PHB | 1 |
| Cancer | Infection of cervical cancer cell lines | 3.05E-02 | PSME2, RANBP1, STIP1 | 3 |
| Cancer | Growth of melanoma | 3.08E-02 | IL1RN | 1 |
| Cancer | Metastasis of melanoma cell lines | 3.20E-02 | NME1 | 1 |
Figure 2Top-scored molecular network with identified proteins implicated in cancer progression according to the IPA software. Proteins in the network are represented by their gene symbols. Green colored shapes denote proteins with lower abundance in oral cancer cell lines, while red colored shapes denote proteins with higher abundance in oral cancer cell lines A) molecule types, B) relationship types.
Figure 3Results of quantitative RT-PCR showing relative expressions of STMN1, 1433S, STIP1 and GSTP1. Total mRNA was extracted from normal and oral cancer cell lines. Quantitative RT-PCR was then performed as described. A: Relative expression of STMN1, B: Relative expression of 1433S, C: Relative expression of STIP1, D: Relative expression of GSTP1. Relative intensities of all genes of interest were determined by using β-actin as an internal standard. Results represent the mean ± SD for three experiments. *p < 0.05.